Hologic, Inc. (NASDAQ:HOLX) – Equities research analysts at Piper Jaffray Companies reduced their Q1 2020 earnings estimates for shares of Hologic in a research report issued on Wednesday, November 6th. Piper Jaffray Companies analyst W. Quirk now forecasts that the medical equipment provider will earn $0.62 per share for the quarter, down from their prior forecast of $0.65. Piper Jaffray Companies currently has a “Overweight” rating and a $59.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Hologic’s Q2 2020 earnings at $0.63 EPS, Q4 2020 earnings at $0.71 EPS, FY2020 earnings at $2.64 EPS, Q1 2021 earnings at $0.67 EPS, Q2 2021 earnings at $0.67 EPS, Q3 2021 earnings at $0.73 EPS, Q4 2021 earnings at $0.77 EPS, FY2021 earnings at $2.84 EPS and FY2022 earnings at $3.09 EPS.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.65. The business had revenue of $865.80 million for the quarter, compared to the consensus estimate of $846.54 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The firm’s revenue was up 6.4% compared to the same quarter last year. During the same period last year, the business earned $0.58 EPS.
A number of other analysts have also issued reports on the company. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a report on Thursday. Canaccord Genuity reaffirmed a “hold” rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $57.00 target price (up previously from $52.00) on shares of Hologic in a report on Thursday, August 1st. ValuEngine lowered Hologic from a “hold” rating to a “sell” rating in a report on Friday, October 25th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $51.48.
HOLX traded up $0.36 during midday trading on Friday, reaching $46.56. The company’s stock had a trading volume of 2,275,800 shares, compared to its average volume of 1,801,821. The stock has a market cap of $12.86 billion, a P/E ratio of 20.30, a PEG ratio of 2.03 and a beta of 0.76. The company has a fifty day simple moving average of $48.95 and a 200 day simple moving average of $47.99. The company has a current ratio of 1.57, a quick ratio of 1.11 and a debt-to-equity ratio of 1.27. Hologic has a twelve month low of $37.48 and a twelve month high of $52.19.
In other news, insider Peter J. Valenti III sold 7,766 shares of Hologic stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total transaction of $381,621.24. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.90% of the stock is currently owned by company insiders.
Several large investors have recently made changes to their positions in HOLX. Nuveen Asset Management LLC grew its holdings in shares of Hologic by 72,308.7% during the 2nd quarter. Nuveen Asset Management LLC now owns 5,304,658 shares of the medical equipment provider’s stock worth $254,730,000 after purchasing an additional 5,297,332 shares in the last quarter. Point72 Asset Management L.P. raised its position in Hologic by 203.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,056,488 shares of the medical equipment provider’s stock valued at $50,733,000 after purchasing an additional 708,361 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Hologic by 22.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,960,574 shares of the medical equipment provider’s stock worth $94,147,000 after acquiring an additional 363,053 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Hologic by 323.0% during the second quarter. AQR Capital Management LLC now owns 415,932 shares of the medical equipment provider’s stock worth $19,973,000 after acquiring an additional 317,614 shares during the last quarter. Finally, Parnassus Investments CA raised its position in shares of Hologic by 1.9% during the third quarter. Parnassus Investments CA now owns 15,825,872 shares of the medical equipment provider’s stock worth $799,048,000 after acquiring an additional 300,090 shares during the last quarter. 95.33% of the stock is currently owned by institutional investors.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.